PROCEPT BioRobotics, which makes a surgical robotic system for minimally-invasive urologic surgery, raised $164 million by offering 6.6 million shares at $25, above the range of $22 to $24. The company offered 1.1 million more shares than anticipated.
PROCEPT BioRobotics is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System, a surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia. Its proprietary AquaBeam Robotic System employs a single-use disposable handpiece to deliver its Aquablation therapy. As of June 30, 2021, PROCEPT BioRobotics had an installed base of 124 AquaBeam Robotic Systems, and Aquablation therapy had been utilized in the treatment of more than 5,500 patients.
PROCEPT BioRobotics plans to list on the Nasdaq under the symbol PRCT. BofA Securities, Goldman Sachs, Cowen, Guggenheim Securities, and SVB Leerink acted as joint bookrunners on the deal.
